Inventor · disambiguated record
Graeme L. Fraser
Also filed as: FRASER GRAEME · FRASER GRAEME L · FRASER GRAEME LOVAT
38 granted patents·8 pending applications·306 citations·filing 2004–2024
97Inventor score
Top patents by PatentIndex Score
46 records- 0195US9422299B2Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsEUROSCREEN SA·Filed 2015·Granted Aug 23, 2016·17 cites·30 claims
- 0295US7491695B2Methods of using macrocyclic modulators of the ghrelin receptorTRANZYME PHARMA INC·Filed 2005·Granted Feb 17, 2009·39 cites·18 claims
- 0395US7476653B2Macrocyclic modulators of the ghrelin receptorTRANZYME PHARMA INC·Filed 2005·Granted Jan 13, 2009·48 cites·14 claims
- 0494USRE42624EMethods of using macrocyclic modulators of the ghrelin receptorTRANZYME PHARMA INC·Filed 2009·Granted Aug 16, 2011·17 cites·18 claims
- 0594US7521420B2Macrocyclic antagonists of the motilin receptorTRANZYME PHARMA INC·Filed 2004·Granted Apr 21, 2009·46 cites·12 claims
- 0692US8088733B2Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disordersFRASER GRAEME L·Filed 2007·Granted Jan 3, 2012·22 cites·16 claims
- 0792USRE42013EMacrocyclic modulators of the ghrelin receptorTRANZYME PHARMA INC·Filed 2009·Granted Dec 28, 2010·18 cites·14 claims
- 0891US8871761B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersEUROSCREEN SA·Filed 2012·Granted Oct 28, 2014·15 cites·12 claims
- 0989US8349887B2Methods of treating cachexia with macrocyclic modulators of the ghrelin receptorTRANZYME PHARMA INC·Filed 2011·Granted Jan 8, 2013·11 cites·6 claims
- 1087US8450268B2Methods of using macrocyclic modulators of the ghrelin receptorFRASER GRAEME L·Filed 2008·Granted May 28, 2013·10 cites·8 claims
- 1185US9987274B2N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsOGEDA SA·Filed 2016·Granted Jun 5, 2018·4 cites·19 claims
- 1285US7452862B2Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonistsTRANZYME PHARMA INC·Filed 2004·Granted Nov 18, 2008·23 cites·4 claims
- 1384US11478472B2NK-3 receptor antagonists for therapeutic treatment of leptin-related diseaseOGEDA SA·Filed 2020·Granted Oct 25, 2022·1 cites·8 claims
- 1483US9475814B2Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofEUROSCREEN SA·Filed 2012·Granted Oct 25, 2016·7 cites·20 claims
- 1582US10836768B2N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsOGEDA SA·Filed 2018·Granted Nov 17, 2020·1 cites·12 claims
- 1682US2024199618A1NOVEL N-ACYL-[3-SUBSTITUTED]-[8-SUBSTITUTED]-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERSOGEDA SA·Filed 2023·Application pending·0 cites
- 1781US10183948B2N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsOGEDA SA·Filed 2017·Granted Jan 22, 2019·1 cites·13 claims
- 1881US7550431B2Spatially-defined macrocycles incorporating peptide bond surrogatesTRANZYME PHARMA INC·Filed 2004·Granted Jun 23, 2009·16 cites·3 claims
- 1980US10624890B2NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fatOGEDA SA·Filed 2016·Granted Apr 21, 2020·2 cites·10 claims
- 2079US9969745B2N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disordersOGEDA SA·Filed 2017·Granted May 15, 2018·2 cites·11 claims
- 2178US12458641B2NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fatOGEDA SA·Filed 2022·Granted Nov 4, 2025·0 cites·4 claims
- 2277US10065961B2Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofEUROSCREEN SA·Filed 2016·Granted Sep 4, 2018·2 cites·5 claims
- 2376US9969738B2N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disordersEUROSCREEN SA·Filed 2014·Granted May 15, 2018·2 cites·9 claims
- 2474US10683295B2Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofOGEDA SA·Filed 2018·Granted Jun 16, 2020·1 cites·5 claims
- 2573US11731974B2N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsOGEDA SA·Filed 2020·Granted Aug 22, 2023·0 cites·8 claims
- 2673US10030025B2Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonistsEUROSCREEN SA·Filed 2016·Granted Jul 24, 2018·1 cites·19 claims
- 2767US10941151B2Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofOGEDA SA·Filed 2020·Granted Mar 9, 2021·0 cites·4 claims
- 2866US12091400B2Piperidine derivatives as METTL3 inhibitorsEPICS THERAPEUTICS·Filed 2024·Granted Sep 17, 2024·0 cites·17 claims
- 2966US2025002475A1Piperidine derivatives as mettl3 inhibitorsEPICS THERAPEUTICS·Filed 2024·Application pending·0 cites
- 3064US2020125564A1Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disordersOGEDA SA·Filed 2019·Application pending·0 cites
- 3162US10258602B2Macrocyclic ghrelin receptor modulators and methods of using the sameOCERA THERAPEUTICS INC·Filed 2018·Granted Apr 16, 2019·0 cites·16 claims
- 3261US9926325B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersOGEDA SA·Filed 2014·Granted Mar 27, 2018·0 cites·4 claims
- 3359US10544150B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersOGEDA SA·Filed 2018·Granted Jan 28, 2020·0 cites·12 claims
- 3458US9840508B2N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disordersEUROSCREEN SA·Filed 2014·Granted Dec 12, 2017·0 cites·12 claims
- 3557US9949949B2Macrocyclic ghrelin receptor modulators and methods of using the sameOCERA THERAPEUTICS INC·Filed 2016·Granted Apr 24, 2018·0 cites·11 claims
- 3657US8557765B2Spatially-defined macrocycles incorporating peptide bond surrogatesDESLONGCHAMPS PIERRE·Filed 2009·Granted Oct 15, 2013·0 cites·2 claims
- 3754US9371297B2Macrocyclic ghrelin receptor modulators and methods of using the sameHOVEYDA HAMID·Filed 2008·Granted Jun 21, 2016·0 cites·4 claims
- 3852US10214533B2N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disordersOGEDA SA·Filed 2018·Granted Feb 26, 2019·0 cites·9 claims
- 3951US9133235B2Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disordersMARSAULT ERIC·Filed 2007·Granted Sep 15, 2015·0 cites·9 claims
- 4051US2008287371A1Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complexTRANZYME PHARMA INC·Filed 2008·Application pending·0 cites
- 4146US2012071412A1Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disordersFRASER GRAEME L·Filed 2011·Application pending·0 cites
- 4244US9770435B2Compounds, pharmaceutical composition and methods for use in treating inflammatory diseasesEUROSCREEN SA·Filed 2014·Granted Sep 26, 2017·0 cites·36 claims
- 4344US2018110824A1Macrocyclic Modulators of the Ghrelin ReceptorOCERA THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4443US2009275648A1Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the sameFRASER GRAEME L·Filed 2006·Application pending·0 cites
- 4536US10065960B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersOGEDA SA·Filed 2015·Granted Sep 4, 2018·0 cites·12 claims
- 4626US2011105389A1Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the SameHOVEYDA HAMID R·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →